Companies · RVTY
Revvity
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Aug 11, 2026
Revvity Q2 FY2026: Diagnostics drives 1% revenue growth as $16.2M tariff refund masks Life Sciences Software weakness and restructuring surge
Revvity's Q2 FY2026 result is a tale of two segments: Diagnostics delivered 5% revenue growth and 520 basis points of operating margin expansion, powered by Reproductive Health strength and a $16.2 million tariff refund, while Life Sciences contracted 2% on a $10.2 million Software revenue decline. The gross margin expansion of 260 basis points to 57.1% is partly one-time in nature, as the tariff refund accounted for the bulk of the improvement. Restructuring charges of $35.5 million — more than triple the prior-year quarter — and accelerating digital investment signal that management is simultaneously cutting costs and building out a new operating infrastructure, with approximately 5% of the workforce affected by severance actions in the first half of FY2026.
Tone: mixedRevenue
$2.9B
RVTY 10-K · FY 2025
Employees
11,000
Revenue growth YoY
+4%
Headquarters
Waltham, MA
Profile
RVTY 10-K Item 1 · Feb 24, 2026Revvity is a health science solutions company operating across two segments — Life Sciences and Diagnostics — serving pharmaceutical, biotech, academic, clinical, and government customers in more than 160 countries. The company provides instruments, reagents, software, and services spanning drug discovery, genomics, reproductive health, and immunodiagnostics. Its strategy combines organic R&D investment with acquisitions to expand capabilities in multi-omics, biomarker identification, imaging, and informatics.
Read filing description ↓ Collapse description ↑
We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Our headquarters are in Waltham, Massachusetts, and we market our products and services in more than 160 countries. Our strategy is to develop and deliver innovative products, services and solutions in high-growth markets that utilize our knowledge and expertise to address customers' critical needs and drive scientific breakthroughs. To execute on our strategy and accelerate revenue growth, we focus on broadening our offerings through both the investment in research and development and the acquisition of innovative technology. Our strategy includes strengthening our position within key markets by expanding our global product and service offerings, maintaining superior product quality and driving an enhanced customer experience; attracting, retaining and developing talented and engaged employees; accelerating transformational innovation through both internal research and development and third-party collaborations and alliances; augmenting growth in both of our core business segments, Life Sciences and Diagnostics, through strategic acquisitions and licensing; advancing the use of Artificial Intelligence to further strengthen our differentiated offerings and to drive internal operating efficiencies; engraining focused operational excellence to improve organizational efficiency and agility; and taking a disciplined approach to capital allocation to support organic investments, pursue mergers and acquisitions and opportunistic share repurchase programs to drive shareholder value.
Primary products
- Reagents
- Instruments
- Software
- Technology and Licensing
- Radiometric detection solutions
- PhenoVue cellular imaging reagents
Business segments
End markets
Geographies
Named customers
“We compete on the basis of service level, price, technological innovation, operational efficiency, product differentiation, product availability, quality and reliability.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Total revenue increased by $101.1 million, or 4%, in fiscal year 2025 versus fiscal year 2024, with Life Sciences segment revenue up 2% and Diagnostics segment revenue up 5%.
The rest of RVTY is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.